James D Wolfe, MD
Allergy/Immunology · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · UCSF Health Medical Foundation · 40 clinicians in this group
Hospitals listed: Dominican Hospital. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wolfe’s office at (650) 701-1882 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G25149 · Current
Licensed to practise in California · since 1973 · expires 2027-04-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$253,279
Medicare paid this office $253,279 for 745 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 479 | $81,363 | $104 |
| Professional service for preparation and provision of 1 or more antigens | 146 | $36,558 | $14 |
| Test for allergy using allergenic extract | 114 | $27,173 | $3 |
| Professional service for multiple injections of allergen | 143 | $22,232 | $11 |
| Test to measure expiratory airflow and volume | 507 | $19,572 | $23 |
See all 14 services
| Return visit (30+ min) | 479 | $81,363 | $104 |
| Professional service for preparation and provision of 1 or more antigens | 146 | $36,558 | $14 |
| Test for allergy using allergenic extract | 114 | $27,173 | $3 |
| Professional service for multiple injections of allergen | 143 | $22,232 | $11 |
| Test to measure expiratory airflow and volume | 507 | $19,572 | $23 |
| Short return visit (20+ min) | 235 | $18,218 | $71 |
| New patient visit (45+ min) | 115 | $15,811 | $137 |
| Test to measure the level of nitric oxide gas | 481 | $13,809 | $17 |
| New patient visit (30+ min) | 45 | $3,802 | $84 |
| Test for allergy using allergenic extract injected into skin | 73 | $3,462 | $8 |
| Pneumococcal vaccine, 23-valent | 14 | $1,831 | $131 |
| Professional service for single injection of allergen | 15 | $1,351 | $8 |
| Administration of pneumococcal vaccine | 14 | $529 | $38 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $342 | $23 |
Who their Medicare patients are
745 Original Medicare patients in 2024. Average age 75 · Under 65 2% · 85 and older 9% · Women 63% · Also on Medicaid 2% · Health risk score 0.95. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 71% · Coronary heart disease 24% · Diabetes 23% · COPD 17% · Atrial fibrillation 15% · Depression 15% · Cancer 13% · Chronic kidney disease 12% · Heart failure 11% · Stroke 5% · Dementia 3%.
The office billed $1,239,031, Medicare allowed $351,045 and paid $253,279; for 17,164 services of 26 kinds; $1,832 of it was for drugs given in the office and $251,446 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 745 | 17,164 | 75 | 0.95 | $1,239,031 | $253,279 |
| 2023 | 705 | 18,938 | 75 | 0.90 | $1,161,044 | $272,498 |
| 2022 | 713 | 21,681 | 75 | 0.86 | $1,206,966 | $296,955 |
| 2021 | 658 | 18,428 | 75 | 0.90 | $918,685 | $287,811 |
| 2020 | 635 | 14,755 | 75 | 0.91 | $631,297 | $252,335 |
| 2019 | 723 | 19,199 | 75 | 0.96 | $747,963 | $308,551 |
| 2018 | 704 | 20,826 | 74 | 0.98 | $762,350 | $296,706 |
| 2017 | 678 | 26,419 | 74 | 0.96 | $834,743 | $346,490 |
| 2016 | 651 | 31,514 | 74 | 0.94 | $1,055,515 | $496,233 |
| 2015 | 611 | 31,484 | 73 | 0.92 | $1,061,263 | $498,987 |
| 2014 | 600 | 27,575 | 73 | 0.91 | $974,494 | $430,023 |
| 2013 | 611 | 25,486 | 73 | 0.91 | $903,668 | $401,985 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 471 | $88,368 | $109 |
| Professional service for preparation and provision of 1 or more antigens | 150 | $38,475 | $15 |
| Test for allergy using allergenic extract | 113 | $31,978 | $4 |
| Professional service for multiple injections of allergen | 144 | $21,180 | $11 |
| Test to measure expiratory airflow and volume | 484 | $21,134 | $24 |
| New patient visit (45+ min) | 130 | $19,557 | $150 |
| Short return visit (20+ min) | 224 | $19,532 | $81 |
| Test to measure the level of nitric oxide gas | 465 | $15,176 | $18 |
| Test for allergy using allergenic extract injected into skin | 82 | $4,152 | $8 |
| New patient visit (30+ min) | 21 | $2,194 | $104 |
| Test for allergy using combination of methods with drug or biological | 12 | $1,946 | $19 |
| Professional service for single injection of allergen | 24 | $1,722 | $9 |
2022: 15 services
| Return visit (30+ min) | 602 | $120,671 | $113 |
| Professional service for preparation and provision of 1 or more antigens | 143 | $36,515 | $15 |
| Test for allergy using allergenic extract | 117 | $33,916 | $4 |
| New patient visit (45+ min) | 158 | $23,647 | $150 |
| Test to measure expiratory airflow and volume | 489 | $21,992 | $25 |
| Professional service for multiple injections of allergen | 162 | $21,268 | $11 |
| Test to measure the level of nitric oxide gas | 462 | $15,814 | $19 |
| Test for allergy using allergenic extract injected into skin | 87 | $4,513 | $9 |
| Test for allergy using combination of methods with drug or biological | 22 | $3,444 | $18 |
| Long return visit (40+ min) | 17 | $3,056 | $161 |
| Test for allergy using ingested items, initial 2 hours | 18 | $2,371 | $119 |
| Professional service for single injection of allergen | 22 | $1,932 | $9 |
| Pneumococcal vaccine, 23-valent | 13 | $1,843 | $132 |
| Short return visit (20+ min) | 11 | $935 | $85 |
| Administration of pneumococcal vaccine | 13 | $521 | $37 |
2021: 12 services
| Return visit (30+ min) | 505 | $103,787 | $115 |
| Professional service for preparation and provision of 1 or more antigens | 144 | $39,401 | $16 |
| Test for allergy using allergenic extract | 106 | $34,627 | $4 |
| Test to measure expiratory airflow and volume | 422 | $23,714 | $29 |
| Professional service for multiple injections of allergen | 139 | $20,550 | $11 |
| New patient visit (45+ min) | 143 | $20,358 | $142 |
| Test to measure the level of nitric oxide gas | 390 | $14,762 | $20 |
| Short return visit (20+ min) | 145 | $12,311 | $70 |
| Test for allergy using combination of methods with drug or biological | 24 | $5,029 | $22 |
| Test for allergy using allergenic extract injected into skin | 72 | $4,303 | $9 |
| Professional service for single injection of allergen | 26 | $1,457 | $8 |
| Test for allergy using ingested items, initial 2 hours | 13 | $1,437 | $111 |
2020: 15 services
| Return visit (30+ min) | 356 | $76,808 | $94 |
| Professional service for preparation and provision of 1 or more antigens | 151 | $36,632 | $13 |
| Test for allergy using allergenic extract | 79 | $26,360 | $4 |
| Test to measure expiratory airflow and volume | 335 | $25,032 | $34 |
| Short return visit (20+ min) | 287 | $22,924 | $60 |
| Professional service for multiple injections of allergen | 159 | $18,742 | $10 |
| New patient visit (45+ min) | 100 | $13,991 | $140 |
| Test to measure the level of nitric oxide gas | 280 | $11,946 | $20 |
| Test for allergy using allergenic extract injected into skin | 59 | $3,603 | $9 |
| Test for allergy using combination of methods with drug or biological | 13 | $3,019 | $22 |
| Long return visit (40+ min) | 22 | $2,687 | $107 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $2,499 | $78 |
| Professional service for single injection of allergen | 24 | $1,806 | $8 |
| Injection of drug or substance under skin or into muscle | 12 | $986 | $13 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $496 | $23 |
2019: 12 services
| Return visit (30+ min) | 312 | $66,359 | $96 |
| Short return visit (20+ min) | 490 | $46,260 | $62 |
| Professional service for preparation and provision of 1 or more antigens | 176 | $42,304 | $13 |
| Test to measure expiratory airflow and volume | 460 | $40,157 | $34 |
| Test for allergy using allergenic extract | 107 | $36,090 | $4 |
| Professional service for multiple injections of allergen | 165 | $21,842 | $9 |
| New patient visit (45+ min) | 148 | $20,039 | $135 |
| Test to measure the level of nitric oxide gas | 366 | $15,808 | $20 |
| Test for allergy using allergenic extract injected into skin | 88 | $5,319 | $8 |
| Long return visit (40+ min) | 23 | $3,417 | $131 |
| Test for allergy using combination of methods with drug or biological | 12 | $2,917 | $21 |
| Professional service for single injection of allergen | 31 | $2,784 | $8 |
2018: 14 services
| Return visit (30+ min) | 282 | $56,904 | $89 |
| Test for allergy using allergenic extract | 97 | $51,176 | $5 |
| Short return visit (20+ min) | 503 | $48,578 | $58 |
| Test to measure expiratory airflow and volume | 461 | $38,358 | $32 |
| Professional service for preparation and provision of 1 or more antigens | 175 | $33,541 | $11 |
| Professional service for multiple injections of allergen | 183 | $19,665 | $8 |
| New patient visit (45+ min) | 131 | $17,111 | $131 |
| Test to measure the level of nitric oxide gas | 390 | $15,719 | $19 |
| Test for allergy using allergenic extract injected into skin | 78 | $4,179 | $8 |
| Long return visit (40+ min) | 21 | $2,520 | $110 |
| Professional service for single injection of allergen | 27 | $2,461 | $6 |
| Test for allergy using ingested items, initial 2 hours | 13 | $1,506 | $108 |
| Pneumococcal vaccine, 23-valent | 11 | $870 | $73 |
| Administration of pneumococcal vaccine | 11 | $305 | $25 |
2017: 14 services
| Test for allergy using allergenic extract | 132 | $96,932 | $6 |
| Short return visit (20+ min) | 531 | $55,414 | $59 |
| Return visit (30+ min) | 226 | $41,626 | $87 |
| Test to measure expiratory airflow and volume | 458 | $38,422 | $32 |
| Professional service for preparation and provision of 1 or more antigens | 171 | $36,784 | $11 |
| Professional service for multiple injections of allergen | 166 | $20,682 | $9 |
| New patient visit (45+ min) | 157 | $20,168 | $128 |
| Test to measure the level of nitric oxide gas | 367 | $14,637 | $18 |
| Test for allergy using allergenic extract injected into skin | 84 | $4,504 | $7 |
| Long return visit (40+ min) | 25 | $3,066 | $118 |
| Test for allergy using combination of methods with drug or biological | 13 | $2,386 | $19 |
| Professional service for single injection of allergen | 26 | $2,204 | $6 |
| Test for allergy using ingested items, initial 2 hours | 11 | $1,131 | $103 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $250 | $17 |
2016: 13 services
| Test for allergy using allergenic extract | 129 | $97,455 | $6 |
| Short return visit (20+ min) | 511 | $52,837 | $61 |
| Return visit (30+ min) | 206 | $44,405 | $91 |
| Test to measure expiratory airflow and volume | 434 | $39,962 | $34 |
| Professional service for preparation and provision of 1 or more antigens | 163 | $38,391 | $12 |
| New patient visit (45+ min) | 162 | $22,072 | $136 |
| Professional service for multiple injections of allergen | 154 | $20,564 | $9 |
| Test to measure the level of nitric oxide gas | 365 | $14,781 | $18 |
| Test for allergy using allergenic extract injected into skin | 94 | $5,274 | $8 |
| Test for allergy using combination of methods with drug or biological | 19 | $3,264 | $20 |
| Professional service for single injection of allergen | 24 | $2,491 | $7 |
| Test for allergy using ingested items, initial 2 hours | 17 | $1,835 | $108 |
| Long return visit (40+ min) | 15 | $1,809 | $106 |
2015: 14 services
| Test for allergy using allergenic extract | 114 | $91,610 | $6 |
| Return visit (30+ min) | 220 | $46,948 | $94 |
| Short return visit (20+ min) | 451 | $46,772 | $62 |
| Professional service for preparation and provision of 1 or more antigens | 156 | $40,832 | $12 |
| Test to measure expiratory airflow and volume | 405 | $39,996 | $35 |
| Professional service for multiple injections of allergen | 154 | $21,455 | $9 |
| New patient visit (45+ min) | 130 | $18,362 | $141 |
| Test to measure the level of nitric oxide gas | 342 | $16,043 | $20 |
| Test for allergy using allergenic extract injected into skin | 90 | $5,583 | $8 |
| Long return visit (40+ min) | 23 | $3,605 | $129 |
| Professional service for single injection of allergen | 21 | $2,730 | $8 |
| Test for allergy using combination of methods with drug or biological | 13 | $2,030 | $19 |
| Test for allergy using ingested items, initial 2 hours | 14 | $1,564 | $112 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $656 | $60 |
2014: 12 services
| Test for allergy using allergenic extract | 96 | $63,588 | $6 |
| Short return visit (20+ min) | 468 | $49,164 | $59 |
| Professional service for preparation and provision of 1 or more antigens | 161 | $41,574 | $11 |
| Test to measure expiratory airflow and volume | 396 | $33,064 | $33 |
| Return visit (30+ min) | 157 | $23,700 | $89 |
| Professional service for multiple injections of allergen | 153 | $20,986 | $9 |
| New patient visit (45+ min) | 125 | $16,552 | $132 |
| Test to measure the level of nitric oxide gas | 357 | $14,224 | $18 |
| Test for allergy using allergenic extract injected into skin | 79 | $4,890 | $7 |
| Professional service for single injection of allergen | 21 | $2,403 | $7 |
| Test for allergy using combination of methods with drug or biological | 13 | $2,387 | $19 |
| Test for allergy using ingested items, initial 2 hours | 12 | $1,282 | $107 |
2013: 13 services
| Test for allergy using allergenic extract | 109 | $68,695 | $7 |
| Short return visit (20+ min) | 480 | $51,937 | $62 |
| Professional service for preparation and provision of 1 or more antigens | 164 | $47,981 | $12 |
| Test to measure expiratory airflow and volume | 407 | $35,229 | $35 |
| Return visit (30+ min) | 208 | $33,446 | $88 |
| Professional service for multiple injections of allergen | 158 | $22,271 | $10 |
| New patient visit (45+ min) | 128 | $17,814 | $139 |
| Test to measure the level of nitric oxide gas | 350 | $16,452 | $20 |
| Test for allergy using allergenic extract injected into skin | 73 | $4,369 | $8 |
| Professional service for single injection of allergen | 23 | $2,943 | $8 |
| Long return visit (40+ min) | 16 | $2,290 | $121 |
| Test for allergy using ingested items, initial 2 hours | 11 | $1,216 | $111 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 11 | $0 | None |
Drugs they prescribed that Part D paid
$1,315,313
Pharmacies billed $1,315,313 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,479) in 2024. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 0%.
1,691 generic and fewer than 11 brand-name prescriptions · $1,315,313 in drug cost · 159 antibiotic prescriptions to 114 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | None | 104 | $402,004 | $3,865 |
| Dupixent | None | 95 | $379,061 | $3,990 |
| Anoro Ellipta | None | 150 | $141,233 | $942 |
| Alvesco | None | 103 | $110,979 | $1,077 |
| Gammagard Liquid | Immune globulin | 12 | $81,502 | $6,792 |
See all 26 drugs
| Dupixent | None | 104 | $402,004 | $3,865 |
| Dupixent | None | 95 | $379,061 | $3,990 |
| Anoro Ellipta | None | 150 | $141,233 | $942 |
| Alvesco | None | 103 | $110,979 | $1,077 |
| Gammagard Liquid | Immune globulin | 12 | $81,502 | $6,792 |
| Trelegy Ellipta | None | 21 | $29,470 | $1,403 |
| Arnuity Ellipta | None | 39 | $17,144 | $440 |
| Azelastine | None | 312 | $14,917 | $48 |
| Spiriva Handihaler | None | 16 | $11,680 | $730 |
| Ipratropium | None | 254 | $11,501 | $45 |
| Hydroxyzine | None | 293 | $10,509 | $36 |
| Fluticasone Propionate Hfa | None | 15 | $7,949 | $530 |
| Clarithromycin | None | 135 | $7,453 | $55 |
| Fluticasone Propionate | None | 42 | $6,248 | $149 |
| Bevespi Aerosphere | None | 11 | $5,809 | $528 |
| Albuterol Sulfate Hfa | None | 170 | $5,649 | $33 |
| Epinephrine | None | 20 | $3,667 | $183 |
| Montelukast | None | 191 | $2,517 | $13 |
| Fluticasone-Salmeterol | None | 14 | $2,433 | $174 |
| Azelastine-Fluticasone | None | 18 | $2,279 | $127 |
| Ventolin Hfa | None | 18 | $1,784 | $99 |
| Prednisone | None | 149 | $1,230 | $8 |
| Cromolyn | None | 38 | $688 | $18 |
| Omeprazole | None | 23 | $366 | $16 |
| Triamcinolone Acetonide | None | 59 | $283 | $5 |
| Hydrocortisone | None | 19 | $98 | $5 |
Year by year
| 2024 | 2,479 | 563 | 0% (0) | None | $1,315,313 |
| 2023 | 2,488 | 533 | 0% (0) | None | $1,192,478 |
| 2022 | 2,342 | 524 | 0% (0) | 31% | $1,037,053 |
| 2021 | 2,122 | 509 | 0% (0) | 33% | $794,274 |
| 2020 | 2,490 | 524 | 0% (0) | 39% | $822,962 |
| 2019 | 2,677 | 583 | 0% (0) | 39% | $741,303 |
| 2018 | 2,746 | 552 | 0% (0) | 43% | $603,176 |
| 2017 | 2,561 | 488 | 0% (0) | 43% | $506,062 |
| 2016 | 2,513 | 477 | 0% (0) | 52% | $551,551 |
| 2015 | 2,351 | 435 | None | 52% | $478,489 |
| 2014 | 2,193 | 446 | 0% (0) | 52% | $433,462 |
| 2013 | 2,159 | 429 | 0% (0) | 54% | $406,216 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Dupixent | None | 91 | $342,155 | $3,760 |
| Dupixent | None | 58 | $222,243 | $3,832 |
| Anoro Ellipta | None | 150 | $155,024 | $1,033 |
| Alvesco | None | 92 | $90,063 | $979 |
| Gammagard Liquid | Immune globulin | 13 | $82,637 | $6,357 |
| Flovent Hfa | None | 89 | $49,154 | $552 |
| Trelegy Ellipta | None | 25 | $24,794 | $992 |
| Azelastine | None | 286 | $16,093 | $56 |
| Symbicort | None | 17 | $13,583 | $799 |
| Hydroxyzine | None | 274 | $13,155 | $48 |
| Clarithromycin | None | 136 | $10,296 | $76 |
| Ipratropium | None | 205 | $9,727 | $47 |
| Advair Diskus | None | 15 | $8,141 | $543 |
| Arnuity Ellipta | None | 20 | $6,754 | $338 |
| Wixela Inhub | None | 16 | $6,743 | $421 |
| Albuterol Sulfate Hfa | None | 143 | $6,589 | $46 |
| Flovent Diskus | None | 12 | $6,342 | $529 |
| Epinephrine | None | 17 | $4,613 | $271 |
| Montelukast | None | 171 | $3,064 | $18 |
| Ventolin Hfa | None | 16 | $2,882 | $180 |
| Azelastine-Fluticasone | None | 20 | $2,466 | $123 |
| Prednisone | None | 195 | $2,202 | $11 |
| Olopatadine | None | 11 | $917 | $83 |
| Fluticasone Propionate | None | 44 | $898 | $20 |
| Cromolyn | None | 31 | $563 | $18 |
| Triamcinolone Acetonide | None | 55 | $518 | $9 |
| Amitriptyline | None | 13 | $331 | $25 |
| Omeprazole | None | 27 | $325 | $12 |
| Azithromycin | None | 14 | $258 | $18 |
| Levofloxacin | None | 18 | $218 | $12 |
| Hydrocortisone | None | 31 | $172 | $6 |
| Levocetirizine Dihydrochloride | None | 13 | $39 | $3 |
2022: 29 drugs
| Dupixent | None | 101 | $373,535 | $3,698 |
| Anoro Ellipta | None | 132 | $120,655 | $914 |
| Alvesco | None | 88 | $94,062 | $1,069 |
| Gammagard Liquid | Immune globulin | 12 | $70,292 | $5,858 |
| Flovent Hfa | None | 89 | $54,677 | $614 |
| Xolair | None | 13 | $33,764 | $2,597 |
| Azelastine | None | 367 | $25,328 | $69 |
| Symbicort | None | 23 | $18,250 | $793 |
| Hydroxyzine | None | 289 | $16,399 | $57 |
| Spiriva Handihaler | None | 16 | $13,809 | $863 |
| Trelegy Ellipta | None | 18 | $13,704 | $761 |
| Advair Hfa | None | 13 | $13,046 | $1,004 |
| Flovent Diskus | None | 15 | $12,297 | $820 |
| Ipratropium | None | 186 | $10,947 | $59 |
| Clarithromycin | None | 122 | $10,607 | $87 |
| Albuterol Sulfate Hfa | None | 120 | $8,237 | $69 |
| Arnuity Ellipta | None | 20 | $7,380 | $369 |
| Wixela Inhub | None | 18 | $7,234 | $402 |
| Montelukast | None | 166 | $3,568 | $21 |
| Epinephrine | None | 13 | $2,973 | $229 |
| Azelastine-Fluticasone | None | 21 | $2,779 | $132 |
| Ventolin Hfa | None | 24 | $2,607 | $109 |
| Prednisone | None | 154 | $1,625 | $11 |
| Fluticasone Propionate | None | 38 | $1,072 | $28 |
| Olopatadine | None | 13 | $769 | $59 |
| Triamcinolone Acetonide | None | 46 | $457 | $10 |
| Cromolyn | None | 14 | $298 | $21 |
| Levocetirizine Dihydrochloride | None | 11 | $149 | $14 |
| Omeprazole | None | 15 | $100 | $7 |
2021: 24 drugs
| Dupixent | 86 | $312,198 | $3,630 |
| Alvesco | 80 | $77,371 | $967 |
| Flovent Hfa | 114 | $68,943 | $605 |
| Anoro Ellipta | 85 | $62,342 | $733 |
| Symbicort | 35 | $25,269 | $722 |
| Trelegy Ellipta | 15 | $19,883 | $1,326 |
| Azelastine | 260 | $16,543 | $64 |
| Flovent Diskus | 22 | $16,448 | $748 |
| Advair Diskus | 16 | $12,485 | $780 |
| Hydroxyzine | 291 | $10,202 | $35 |
| Ipratropium | 156 | $9,725 | $62 |
| Albuterol Sulfate Hfa | 121 | $8,711 | $72 |
| Arnuity Ellipta | 23 | $7,847 | $341 |
| Wixela Inhub | 18 | $6,957 | $387 |
| Clarithromycin | 74 | $6,156 | $83 |
| Epinephrine | 23 | $5,640 | $245 |
| Incruse Ellipta | 12 | $5,566 | $464 |
| Azelastine-Fluticasone | 20 | $3,894 | $195 |
| Montelukast | 194 | $3,764 | $19 |
| Ventolin Hfa | 24 | $2,495 | $104 |
| Fluticasone Propionate | 47 | $1,669 | $36 |
| Prednisone | 114 | $1,324 | $12 |
| Triamcinolone Acetonide | 87 | $871 | $10 |
| Hydrocortisone | 14 | $96 | $7 |
2020: 32 drugs
| Dupixent | 71 | $249,406 | $3,513 |
| Alvesco | 155 | $134,321 | $867 |
| Flovent Hfa | 169 | $89,871 | $532 |
| Anoro Ellipta | 93 | $53,022 | $570 |
| Symbicort | 45 | $24,014 | $534 |
| Spiriva | 20 | $18,584 | $929 |
| Trelegy Ellipta | 15 | $16,029 | $1,069 |
| Azelastine | 247 | $15,018 | $61 |
| Advair Diskus | 16 | $14,244 | $890 |
| Arnuity Ellipta | 40 | $14,125 | $353 |
| Hydroxyzine | 292 | $13,723 | $47 |
| Breo Ellipta | 25 | $13,460 | $538 |
| Serevent Diskus | 12 | $12,707 | $1,059 |
| Flovent Diskus | 15 | $10,611 | $707 |
| Albuterol Sulfate Hfa | 137 | $10,271 | $75 |
| Pulmicort Flexhaler | 21 | $9,704 | $462 |
| Clarithromycin | 109 | $8,249 | $76 |
| Ipratropium | 119 | $8,192 | $69 |
| Wixela Inhub | 20 | $7,344 | $367 |
| Bevespi Aerosphere | 13 | $7,242 | $557 |
| Azelastine-Fluticasone | 24 | $5,909 | $246 |
| Epinephrine | 11 | $4,400 | $400 |
| Proair Hfa | 30 | $3,896 | $130 |
| Ventolin Hfa | 48 | $3,731 | $78 |
| Montelukast | 203 | $3,668 | $18 |
| Olopatadine | 24 | $2,518 | $105 |
| Fluticasone Propionate | 62 | $2,110 | $34 |
| Prednisone | 147 | $1,656 | $11 |
| Mometasone Furoate | 13 | $990 | $76 |
| Triamcinolone Acetonide | 74 | $810 | $11 |
| Omeprazole | 24 | $572 | $24 |
| Hydrocortisone | 22 | $110 | $5 |
2019: 31 drugs
| Dupixent | 46 | $141,972 | $3,086 |
| Alvesco | 122 | $112,744 | $924 |
| Flovent Hfa | 188 | $98,108 | $522 |
| Anoro Ellipta | 95 | $52,683 | $555 |
| Advair Diskus | 53 | $33,213 | $627 |
| Symbicort | 53 | $28,167 | $531 |
| Arnuity Ellipta | 74 | $24,685 | $334 |
| Spiriva | 26 | $20,179 | $776 |
| Clarithromycin | 227 | $16,597 | $73 |
| Trelegy Ellipta | 15 | $14,544 | $970 |
| Azelastine | 242 | $14,528 | $60 |
| Flovent Diskus | 28 | $13,760 | $491 |
| Serevent Diskus | 15 | $12,506 | $834 |
| Pulmicort Flexhaler | 27 | $12,218 | $453 |
| Hydroxyzine | 258 | $11,369 | $44 |
| Breo Ellipta | 20 | $10,567 | $528 |
| Dymista | 27 | $8,765 | $325 |
| Ipratropium | 118 | $7,063 | $60 |
| Wixela Inhub | 21 | $7,062 | $336 |
| Proair Hfa | 53 | $6,847 | $129 |
| Ventolin Hfa | 59 | $5,383 | $91 |
| Albuterol Sulfate Hfa | 58 | $3,266 | $56 |
| Montelukast | 153 | $3,172 | $21 |
| Prednisone | 284 | $2,914 | $10 |
| Olopatadine | 32 | $2,892 | $90 |
| Fluticasone Propionate | 78 | $1,928 | $25 |
| Omeprazole | 29 | $802 | $28 |
| Amoxicillin-Clavulanate Potass | 23 | $696 | $30 |
| Triamcinolone Acetonide | 55 | $551 | $10 |
| Hydrocortisone | 25 | $137 | $5 |
| Cromolyn | 11 | $110 | $10 |
2018: 31 drugs
| Alvesco | 163 | $119,374 | $732 |
| Flovent Hfa | 233 | $97,296 | $418 |
| Anoro Ellipta | 84 | $51,046 | $608 |
| Advair Diskus | 80 | $44,285 | $554 |
| Symbicort | 60 | $26,965 | $449 |
| Arnuity Ellipta | 74 | $22,025 | $298 |
| Spiriva | 32 | $20,954 | $655 |
| Flovent Diskus | 55 | $19,205 | $349 |
| Serevent Diskus | 24 | $17,309 | $721 |
| Pulmicort Flexhaler | 43 | $17,274 | $402 |
| Dymista | 41 | $15,876 | $387 |
| Clarithromycin | 201 | $15,850 | $79 |
| Hydroxyzine | 227 | $13,170 | $58 |
| Azelastine | 205 | $11,165 | $54 |
| Advair Hfa | 12 | $9,689 | $807 |
| Proair Hfa | 81 | $8,729 | $108 |
| Ventolin Hfa | 85 | $6,413 | $75 |
| Ipratropium | 142 | $6,002 | $42 |
| Breo Ellipta | 11 | $4,968 | $452 |
| Prednisone | 289 | $3,198 | $11 |
| Montelukast | 146 | $3,192 | $22 |
| Mometasone Furoate | 14 | $2,946 | $210 |
| Fluticasone Propionate | 95 | $1,665 | $18 |
| Levofloxacin | 15 | $1,281 | $85 |
| Olopatadine | 11 | $1,181 | $107 |
| Fluocinonide | 14 | $919 | $66 |
| Triamcinolone Acetonide | 55 | $570 | $10 |
| Ranitidine | 23 | $396 | $17 |
| Amoxicillin-Clavulanate Potass | 14 | $336 | $24 |
| Omeprazole | 19 | $209 | $11 |
| Hydrocortisone | 16 | $95 | $6 |
2017: 33 drugs
| Alvesco | 152 | $88,439 | $582 |
| Flovent Hfa | 185 | $82,670 | $447 |
| Advair Diskus | 104 | $53,723 | $517 |
| Anoro Ellipta | 87 | $32,938 | $379 |
| Arnuity Ellipta | 91 | $26,472 | $291 |
| Spiriva | 41 | $25,077 | $612 |
| Serevent Diskus | 24 | $18,010 | $750 |
| Pulmicort Flexhaler | 30 | $13,460 | $449 |
| Clarithromycin | 177 | $13,212 | $75 |
| Symbicort | 30 | $12,130 | $404 |
| Azelastine | 210 | $11,981 | $57 |
| Dymista | 33 | $10,400 | $315 |
| Flovent Diskus | 33 | $9,951 | $302 |
| Proair Hfa | 88 | $9,790 | $111 |
| Hydroxyzine | 212 | $9,761 | $46 |
| Asmanex | 20 | $8,332 | $417 |
| Ipratropium | 116 | $5,283 | $46 |
| Breo Ellipta | 12 | $3,884 | $324 |
| Ventolin Hfa | 42 | $3,756 | $89 |
| Mometasone Furoate | 13 | $3,256 | $250 |
| Qvar | 13 | $3,170 | $244 |
| Montelukast | 153 | $2,764 | $18 |
| Prednisone | 245 | $2,713 | $11 |
| Fluticasone Propionate | 109 | $2,432 | $22 |
| Theophylline Anhydrous | 14 | $1,871 | $134 |
| Levofloxacin | 37 | $1,382 | $37 |
| Omeprazole | 27 | $725 | $27 |
| Triamcinolone Acetonide | 41 | $465 | $11 |
| Amoxicillin-Clavulanate Potass | 18 | $396 | $22 |
| Ranitidine | 18 | $282 | $16 |
| Ciprofloxacin | 14 | $149 | $11 |
| Hydrocortisone | 12 | $78 | $7 |
| Nystatin | 11 | $68 | $6 |
2016: 31 drugs
| Alvesco | 257 | $151,825 | $591 |
| Flovent Hfa | 168 | $68,567 | $408 |
| Advair Diskus | 101 | $54,216 | $537 |
| Spiriva | 55 | $29,386 | $534 |
| Flovent Diskus | 70 | $19,611 | $280 |
| Serevent Diskus | 24 | $17,525 | $730 |
| Anoro Ellipta | 42 | $17,334 | $413 |
| Dymista | 47 | $17,001 | $362 |
| Symbicort | 39 | $16,627 | $426 |
| Pulmicort Flexhaler | 35 | $15,694 | $448 |
| Azelastine | 237 | $13,587 | $57 |
| Asmanex | 35 | $13,325 | $381 |
| Arnuity Ellipta | 42 | $13,146 | $313 |
| Clarithromycin | 140 | $10,977 | $78 |
| Proair Hfa | 92 | $9,523 | $104 |
| Hydroxyzine | 162 | $4,589 | $28 |
| Nasonex | 11 | $4,483 | $408 |
| Montelukast | 149 | $4,021 | $27 |
| Ipratropium | 111 | $3,432 | $31 |
| Amoxicillin-Clavulanate Pot Er | 18 | $3,091 | $172 |
| Ventolin Hfa | 31 | $2,759 | $89 |
| Fluticasone Propionate | 130 | $2,220 | $17 |
| Prednisone | 181 | $2,082 | $12 |
| Olopatadine | 11 | $1,852 | $168 |
| Theophylline Anhydrous | 17 | $1,237 | $73 |
| Levofloxacin | 34 | $1,204 | $35 |
| Azithromycin | 13 | $551 | $42 |
| Ranitidine | 26 | $420 | $16 |
| Omeprazole | 37 | $376 | $10 |
| Triamcinolone Acetonide | 22 | $211 | $10 |
| Lansoprazole | 13 | $161 | $12 |
2015: 28 drugs
| Alvesco | 257 | $142,884 | $556 |
| Flovent Hfa | 160 | $59,098 | $369 |
| Spiriva | 69 | $40,730 | $590 |
| Advair Diskus | 97 | $39,272 | $405 |
| Flovent Diskus | 69 | $16,594 | $240 |
| Azelastine | 215 | $14,469 | $67 |
| Pulmicort Flexhaler | 35 | $12,590 | $360 |
| Symbicort | 28 | $12,400 | $443 |
| Dymista | 39 | $11,717 | $300 |
| Proair Hfa | 99 | $11,444 | $116 |
| Clarithromycin | 133 | $10,017 | $75 |
| Serevent Diskus | 13 | $8,927 | $687 |
| Hydroxyzine | 135 | $7,429 | $55 |
| Epipen 2-Pak | 14 | $7,184 | $513 |
| Asmanex | 14 | $5,508 | $393 |
| Foradil | 16 | $5,450 | $341 |
| Ipratropium | 139 | $4,507 | $32 |
| Amoxicillin-Clavulanate Pot Er | 17 | $3,367 | $198 |
| Montelukast | 140 | $3,361 | $24 |
| Fluticasone Propionate | 183 | $3,073 | $17 |
| Ventolin Hfa | 18 | $1,554 | $86 |
| Prednisone | 128 | $1,317 | $10 |
| Levofloxacin | 35 | $1,052 | $30 |
| Theophylline Anhydrous | 20 | $525 | $26 |
| Lansoprazole | 13 | $407 | $31 |
| Triamcinolone Acetonide | 28 | $283 | $10 |
| Ranitidine | 18 | $225 | $12 |
| Omeprazole | 22 | $220 | $10 |
2014: 32 drugs
| Alvesco | 247 | $125,726 | $509 |
| Flovent Hfa | 167 | $51,992 | $311 |
| Advair Diskus | 104 | $39,891 | $384 |
| Spiriva | 67 | $32,902 | $491 |
| Azelastine | 201 | $18,392 | $92 |
| Flovent Diskus | 71 | $15,765 | $222 |
| Symbicort | 35 | $12,427 | $355 |
| Patanol | 20 | $12,351 | $618 |
| Clarithromycin | 111 | $10,574 | $95 |
| Proair Hfa | 87 | $8,878 | $102 |
| Serevent Diskus | 13 | $6,645 | $511 |
| Advair Hfa | 13 | $6,641 | $511 |
| Dymista | 18 | $6,504 | $361 |
| Pulmicort Flexhaler | 22 | $6,282 | $286 |
| Fluticasone Propionate | 206 | $5,544 | $27 |
| Ipratropium | 118 | $5,085 | $43 |
| Hydroxyzine | 157 | $5,031 | $32 |
| Pataday | 14 | $4,912 | $351 |
| Nasonex | 17 | $4,729 | $278 |
| Veramyst | 11 | $4,490 | $408 |
| Montelukast | 105 | $4,137 | $39 |
| Singulair | 14 | $4,067 | $291 |
| Astepro | 18 | $3,666 | $204 |
| Amoxicillin-Clavulanate Er | 12 | $1,879 | $157 |
| Lansoprazole | 12 | $732 | $61 |
| Triamcinolone Acetonide | 42 | $712 | $17 |
| Prednisone | 59 | $704 | $12 |
| Ventolin Hfa | 16 | $671 | $42 |
| Levofloxacin | 17 | $481 | $28 |
| Ranitidine | 22 | $463 | $21 |
| Theophylline Anhydrous | 14 | $458 | $33 |
| Omeprazole | 17 | $258 | $15 |
2013: 29 drugs
| Alvesco | 286 | $108,004 | $378 |
| Advair Diskus | 144 | $49,079 | $341 |
| Flovent Hfa | 127 | $42,998 | $339 |
| Spiriva | 58 | $25,585 | $441 |
| Azelastine | 154 | $17,141 | $111 |
| Clarithromycin | 116 | $15,489 | $134 |
| Serevent Diskus | 30 | $11,492 | $383 |
| Flovent Diskus | 57 | $11,041 | $194 |
| Patanol | 19 | $9,512 | $501 |
| Proair Hfa | 81 | $8,729 | $108 |
| Fluticasone Propionate | 206 | $8,521 | $41 |
| Nasonex | 24 | $8,442 | $352 |
| Symbicort | 31 | $8,205 | $265 |
| Hydroxyzine | 174 | $6,972 | $40 |
| Advair Hfa | 15 | $6,669 | $445 |
| Montelukast | 99 | $6,585 | $67 |
| Singulair | 22 | $6,239 | $284 |
| Astepro | 27 | $4,462 | $165 |
| Dymista | 15 | $4,365 | $291 |
| Ipratropium | 115 | $4,310 | $37 |
| Amoxicillin-Clavulanate Er | 15 | $2,437 | $162 |
| Arcapta Neohaler | 11 | $2,301 | $209 |
| Ventolin Hfa | 18 | $1,284 | $71 |
| Triamcinolone Acetonide | 42 | $724 | $17 |
| Levofloxacin | 34 | $598 | $18 |
| Theophylline Anhydrous | 14 | $431 | $31 |
| Omeprazole | 13 | $375 | $29 |
| Ranitidine | 13 | $236 | $18 |
| Prednisone | 26 | $232 | $9 |
Money from drug and device companies
$1,752 in 2025
| 2025 | 13 | 109 | None | $1,752 |
| 2024 | 10 | 65 | $170,237 | $171,226 |
| 2023 | 9 | 50 | None | $1,020 |
| 2022 | 8 | 56 | None | $944 |
| 2021 | 5 | 60 | None | $917 |
| 2020 | 10 | 57 | None | $1,023 |
| 2019 | 15 | 101 | None | $1,479 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Fasenra | $753 | 30 payments
|
| GlaxoSmithKline | Nucala | $226 | 11 payments
|
| ARS Pharmaceuticals Operations | Neffy | $212 | 17 payments
|
| Novartis Pharmaceuticals | Xolair | $168 | 8 payments
|
| Genzyme | Dupixent | $114 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $83 | 3 payments
|
See all 81 published payments
| GlaxoSmithKline | Meals · 2025-12-17 | Nucala | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-17 | Tezspire | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-10 | Fasenra | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-12-08 | Dupixent | $26 |
| Novartis Pharmaceuticals | Meals · 2025-11-26 | Xolair | $30 |
| Genzyme | Meals · 2025-11-20 | Dupixent | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-19 | Tezspire | $25 |
| GlaxoSmithKline | Meals · 2025-11-17 | Nucala | $25 |
| Novartis Pharmaceuticals | Meals · 2025-11-17 | Xolair | $8 |
| ARS Pharmaceuticals Operations | Meals · 2025-11-15 | Neffy | $2 |
| ARS Pharmaceuticals Operations | Meals · 2025-11-14 | Neffy | $10 |
| ARS Pharmaceuticals Operations | Meals · 2025-11-14 | Neffy | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-12 | Fasenra | $16 |
| Amgen | Meals · 2025-11-05 | Tezspire | $15 |
| Paratek Pharmaceuticals | Meals · 2025-10-31 | Xhance | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-29 | Tezspire | $21 |
| Novartis Pharmaceuticals | Meals · 2025-10-27 | Xolair | $3 |
| CSL Behring | Meals · 2025-10-27 | Hizentra | $37 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-24 | Fasenra | $18 |
| GlaxoSmithKline | Meals · 2025-10-21 | Nucala | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-15 | Tezspire | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-10 | Fasenra | $15 |
| Novartis Pharmaceuticals | Meals · 2025-10-08 | Xolair | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-07 | Tezspire | $18 |
| Ionis Pharmaceuticals | Meals · 2025-10-07 | Dawnzera | $20 |
| Genzyme | Meals · 2025-10-06 | Dupixent | $14 |
| CSL Behring | Meals · 2025-10-04 | Andembry | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-29 | Tezspire | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-26 | Fasenra | $20 |
| GlaxoSmithKline | Meals · 2025-09-16 | Nucala | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-12 | Fasenra | $16 |
| Novartis Pharmaceuticals | Meals · 2025-09-10 | Xolair | $28 |
| ARS Pharmaceuticals Operations | Meals · 2025-09-10 | Neffy | $17 |
| ARS Pharmaceuticals Operations | Meals · 2025-09-06 | Neffy | $8 |
| ARS Pharmaceuticals Operations | Meals · 2025-09-05 | Neffy | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-04 | Tezspire | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-03 | Tezspire | $24 |
| Genzyme | Meals · 2025-08-29 | Dupixent | $38 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-23 | Tezspire | $16 |
| GlaxoSmithKline | Meals · 2025-08-18 | Nucala | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-15 | Fasenra | $22 |
| Novartis Pharmaceuticals | Meals · 2025-08-13 | Xolair | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-05 | Tezspire | $24 |
| ARS Pharmaceuticals Operations | Meals · 2025-08-01 | Neffy | $28 |
| ARS Pharmaceuticals Operations | Meals · 2025-08-01 | Neffy | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-30 | Fasenra | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-25 | Tezspire | $24 |
| GlaxoSmithKline | Meals · 2025-07-23 | Nucala | $21 |
| Grifols USA | Meals · 2025-07-21 | Xembify | $28 |
| Novartis Pharmaceuticals | Meals · 2025-07-09 | Xolair | $18 |
| ARS Pharmaceuticals Operations | Meals · 2025-06-21 | Neffy | $7 |
| ARS Pharmaceuticals Operations | Meals · 2025-06-20 | Neffy | $27 |
| Novartis Pharmaceuticals | Meals · 2025-06-18 | Xolair | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-16 | Fasenra | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Fasenra | $13 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-07 | Tezspire | $16 |
| GlaxoSmithKline | Meals · 2025-05-20 | Trelegy Ellipta | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-17 | Tezspire | $17 |
| ARS Pharmaceuticals Operations | Meals · 2025-05-16 | Neffy | $11 |
| Regeneron Healthcare Solutions | Meals · 2025-05-12 | Dupixent | $27 |
| GlaxoSmithKline | Meals · 2025-04-22 | Nucala | $10 |
| Genzyme | Meals · 2025-04-21 | Dupixent | $41 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-18 | Tezspire | $26 |
| GlaxoSmithKline | Meals · 2025-04-13 | Nucala | $34 |
| GlaxoSmithKline | Meals · 2025-04-10 | Nucala | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-09 | Fasenra | $21 |
| Pfizer | Meals · 2025-04-07 | Cibinqo | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-24 | Tezspire | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-14 | Fasenra | $17 |
| Viatris Specialty | Meals · 2025-03-10 | Yupelri | $21 |
| ARS Pharmaceuticals Operations | Meals · 2025-03-08 | Neffy | $1 |
| ARS Pharmaceuticals Operations | Meals · 2025-03-08 | Neffy | $10 |
| Regeneron Healthcare Solutions | Meals · 2025-03-03 | Dupixent | $30 |
| ARS Pharmaceuticals Operations | Meals · 2025-02-20 | Neffy | $3 |
| ARS Pharmaceuticals Operations | Meals · 2025-02-20 | Neffy | $12 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-05 | Fasenra | $18 |
| GlaxoSmithKline | Meals · 2025-01-31 | Nucala | $12 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-24 | Tezspire | $18 |
| ARS Pharmaceuticals Operations | Meals · 2025-01-23 | Neffy | $10 |
| ARS Pharmaceuticals Operations | Meals · 2025-01-23 | Neffy | $1 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-08 | Fasenra | $168 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $171,226
| Cipla USA | None | $170,237 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $563 | 17 payments
|
| GlaxoSmithKline | Nucala | $96 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $89 | 3 payments
|
| Novartis Pharmaceuticals | Xolair | $88 | 5 payments
|
| Hikma Pharmaceuticals USA | Ryaltris | $40 | 2 payments
|
| Philips North America | (8874) Incourage | $38 | 2 payments
|
| LEO Pharma | Adbry | $26 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $25 | 1 payment
|
| Lilly USA | Ebglyss | $24 | 1 payment
|
2023: $1,020
| AstraZeneca Pharmaceuticals LP | Breztri | $606 | 16 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $144 | 9 payments
|
| Novartis Pharmaceuticals | Xolair | $72 | 4 payments
|
| Merck Sharp & Dohme | None | $66 | 2 payments
|
| Hikma Pharmaceuticals USA | Ryaltris | $33 | 2 payments
|
| Pfizer | Cibinqo | $31 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $28 | 1 payment
|
| Optinose US | Xhance | $26 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $15 | 1 payment
|
2022: $944
| AstraZeneca Pharmaceuticals LP | Fasenra | $539 | 25 payments
|
| GlaxoSmithKline | Nucala | $249 | 15 payments
|
| Mylan Specialty L.P. | Yupelri | $40 | 2 payments
|
| Covis Pharma GmBH | Alvesco | $32 | 1 payment
|
| CSL Behring | Hizentra | $24 | 1 payment
|
| OptiNose US | Xhance | $22 | 1 payment
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $15 | 1 payment
|
2021: $917
| GlaxoSmithKline | Nucala | $444 | 27 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $344 | 19 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $80 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $25 | 1 payment
|
| kaleo | Auvi-Q | $24 | 1 payment
|
2020: $1,023
| GlaxoSmithKline | Nucala | $373 | 25 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $231 | 15 payments
|
| Genzyme | Dupixent | $168 | 3 payments
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $72 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $45 | 2 payments
|
| OptiNose US | Xhance | $39 | 2 payments
|
| Advanced Respiratory | The Vest System Model 105 Home Care | $25 | 1 payment
|
| Covis Pharma GmbH | Alvesco | $24 | 1 payment
|
| Novartis Pharmaceuticals | Xolair | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $22 | 1 payment
|
2019: $1,479
| GlaxoSmithKline | Nucala | $450 | 35 payments
|
| AstraZeneca Pharmaceuticals LP | Bevespi Aerosphere | $212 | 10 payments
|
| ALK-Abello | Odactra | $206 | 17 payments
|
| Novartis Pharmaceuticals | Xolair | $98 | 5 payments
|
| Shire North American Group | Takhzyro | $84 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $78 | 4 payments
|
| OptiNose US | Xhance | $67 | 3 payments
|
| Teva Pharmaceuticals USA | Cinqair | $64 | 3 payments
|
| Genzyme | Dupixent | $60 | 3 payments
|
| Kaleo | Auvi-Q | $36 | 2 payments
|
| Mylan Specialty L.P. | Yupelri | $35 | 2 payments
|
| Pfizer | Panzyga | $27 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $22 | 1 payment
|
| Genentech USA | Xolair | $22 | 1 payment
|
| Covis Pharma B.V. | Alvesco | $17 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · A 24-Week Efficacy and Safety Study To Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2022 | Their institution | $230,266 |
| Amphastar Pharmaceuticals, Inc. · Phamacodynamic (Pd) Bronchodilatation Bioequivalence (Be) Study of Albuterol Sulfate Hfa Mdi 90 Mcg/Inhalation in Asthma Patients · 2020 | Their institution | $180,746 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study To Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 Mcg/50 Mcg To Advair Diskus 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma · 2019 | Their institution | $151,170 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double-Blind Parallel Group Multicenter 12 Week Study To Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative To Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma · 2023 | Their institution | $142,904 |
| Amphastar Pharmaceuticals, Inc. · Pharmacodynamic (Pd) Bronchodilatation Bioequivalence (Be) Study of Albuterol Sulfate Hfa Mdi 90 Mcg/Inhalation in Asthma Patients · 2019 | Their institution | $140,451 |
| AstraZeneca Pharmaceuticals LP · A Randomized, Placebo-Controlled, Double-Blind, Multicenter, 12 Week, 3-Way, Partial-Replicate Crossover Pharmacodynamic Study To Assess the Equivalence of Budesonide and Albuterol (Bda) Delivered By Mdi Hfo Compared With Bda Delivered By Mdi Hfa in Participants With Asthma · 2025 | Their institution | $127,480 |
| AstraZeneca Pharmaceuticals LP · A Phase 2 Randomized Double Blind Placebo Controlled Dose Regimen Range Finding Study To Assess Efficacy and Safety of Subcutaneous Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium To High Dose Inhaled Corticosteroids · 2025 | Their institution | $117,349 |
| AstraZeneca Pharmaceuticals LP · Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study To Assess Efficacy and Safety of Multiple Dose Levels of Inhaled Azd8630 · 2025 | Their institution | $110,897 |
| Chiesi USA, Inc. · A 12 Week, Randomized, Double-Blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of Chf 1535 Pmdi 800/24?G Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compared To Chf 718 Pmdi 800?G Total Daily Dose (Extrafine Beclomethasone Dipropionate) in Adults With Asthma on Medium Or High-Dose Inhaled Corticosteroid. · 2023 | Their institution | $106,626 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Open Label, Active-Controlled, Parallel-Group, Multiple-Dose, Multiple-Site, Patient Use Study To Obtain Partially Used Test Fluticasone Propionate Inhalation Aerosol, 110 Mcg (Teva) Devices and Reference Flovent Hfa (Fluticasone Propionate Inhalation Aerosol), 110 Mcg (Glaxosmithkline) Devices, After Repeated Use in Patients With Asthma · 2024 | Their institution | $100,906 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study To Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 Mcg, To Flovent Hfa 110 Mcg, in Adult Subjects With Asthma · 2019 | Their institution | $92,606 |
| Chiesi USA, Inc. · A 12 Week, Randomized, Double-Blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of Chf 1535 Pmdi 800/24g Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compared To Chf 718 Pmdi 800g Total Daily Dose (Extrafine Beclomethasone Dipropionate) in Adults With Asthma on Medium Or High-Dose Inhaled Corticosteroid. · 2024 | Their institution | $82,424 |
| AstraZeneca UK Limited · A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study To Assess Efficacy and Safety of Multiple Dose Levels of Azd5718 Given Orally Once Daily for Twelve Weeks in Adults With Moderate-To-Severe Uncontrolled Asthma · 2024 | Their institution | $71,085 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study To Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 Mcg, To Flovent Hfa 110 Mcg, in Adult Subjects With Asthma · 2020 | Their institution | $62,028 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Sar443765 in Adult Participants With Moderate To Severe Asthma · 2025 | Their institution | $60,489 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study To Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 Mcg, To Flovent Hfa 110 Mcg, in Adult Subjects With Asthma · 2021 | Their institution | $59,834 |
| AstraZeneca UK Limited · Phase I, Randomised, Blinded, Placebo-Controlled Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Azd8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium To High Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists (Part B) · 2023 | Their institution | $47,902 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double-Blind Parallel Group Multicenter 12 Week Study To Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative To Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma · 2024 | Their institution | $46,076 |
| AstraZeneca Pharmaceuticals LP · Phase I, Randomised, Blinded, Placebo-Controlled Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Azd8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium To High Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists (Part B) · 2023 | Their institution | $39,766 |
| Novartis Pharmaceuticals Corporation · A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study To Assess the Efficacy and Safety of Qaw039 When Added To Standard of Care Asthma Therapy in Patients With Uncontrolled Asthma · 2019 | Their institution | $38,257 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double-Blind Parallel Group Multicenter 12 Week Study To Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative To Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma · 2025 | Their institution | $35,356 |
| Amphastar Pharmaceuticals, Inc. · Pharmacodynamic (Pd) Bronchodilatation Bioequivalence (Be) Study of Albuterol Sulfate Hfa Mdi 90 Mcg/Inhalation in Asthma Patients · 2021 | Their institution | $34,081 |
| PFIZER INC. · A Phase 2 Randomized Doubleblind Placebocontrolled Parallelgroup Doseranging Study To Investigate the Efficacy and Safety of Pf07275315 in Adult Participants With Inadequately Controlled Moderatetosevere Asthma · 2025 | Their institution | $33,788 |
| AstraZeneca UK Limited · A Phase Two A,Randomized,Double Blind,Placebo Controlled Study To Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate To Severe Uncontrolled Asthma · 2025 | Their institution | $29,656 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study To Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 Mcg/50 Mcg To Advair Diskus 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma · 2020 | Their institution | $28,980 |
| GlaxoSmithKline, LLC. · A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Dose Find · 2025 | Their institution | $28,464 |
| AstraZeneca Pharmaceuticals LP · A Randomized, Placebo-Controlled, Double-Blind, Multicenter, 12 Week, 3-Way, Partial-Replicate Crossover Pharmacodynamic Study To Assess the Equivalence of Budesonide and Albuterol (Bda) Delivered By Mdi Hfo Compared With Bda Delivered By Mdi Hfa in Participants With Asthma · 2024 | Their institution | $26,993 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Sar443765 in Adult Participants With Moderate To Severe Asthma · 2024 | Their institution | $26,686 |
| AstraZeneca Pharmaceuticals LP · A 24-Week Efficacy and Safety Study To Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2024 | Their institution | $24,483 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized 52 Weeks Treatment Double Blind Triple Dummy Study To Assess the Efficacy and Safety of Qmf149 Compared With Mometasone Furoate and Salmeterol Fluticasone · 2019 | Their institution | $19,573 |
| CIPLA USA INC. · A Randomized, Single-Dose, Double-Blind, Placebo-Controlled, Four-Way Crossover, Multicenter Bronchoprovocation Study Comparing the Bronchoprotective Effects of Albuterol Sulfate Inhalation Aerosol (90 Mcg, Invagen/Cipla) With Ventolin Hfa (90 Mcg, Glaxosmithkline) in Adult Asthma Patients. · 2025 | Their institution | $15,180 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Randomized, Double-Blind, Single-Dose, Placebo-Controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study To Compare the Bronchodilatory Effect and Safety of Pt007 As Mdi To Placebo Mdi and Open-Label Ventolin Evohaler in Adult Participants With Asthma Mitchell · 2025 | Their institution | $10,863 |
| AstraZeneca Pharmaceuticals LP · A 24-Week Efficacy and Safety Study To Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2025 | Their institution | $10,320 |
| AstraZeneca UK Limited · A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study To Assess Efficacy and Safety of Multiple Dose Levels of Azd5718 Given Orally Once Daily for Twelve Weeks in Adults With Moderate-To-Severe Uncontrolled Asthma · 2023 | Their institution | $9,461 |
| Novartis Pharmaceuticals Corporation · A 52 Week Multicenter Randomized Double Blind Placebocontrolled Study To Assess the Efficacy and Safety of Qaw039 When Added To Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma · 2019 | Their institution | $7,647 |
| AstraZeneca Pharmaceuticals LP · A 24-Week Efficacy and Safety Study To Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2023 | Their institution | $6,163 |
| Chiesi USA, Inc. · A 12 Week, Randomized, Double-Blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of Chf 1535 Pmdi 800/24?G Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compared To Chf 718 Pmdi 800?G Total Daily Dose (Extrafine Beclomethasone Dipropionate) in Adults With Asthma on Medium Or High-Dose Inhaled Corticosteroid. · 2025 | Their institution | $2,541 |
| AstraZeneca UK Limited · Phase I, Randomised, Blinded, Placebo-Controlled Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Azd8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium To High Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists (Part B) · 2024 | Their institution | $2,049 |
| AstraZeneca Pharmaceuticals LP · Phase I, Randomised, Blinded, Placebo-Controlled Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Azd8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium To High Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists (Part B) · 2024 | Their institution | $1,834 |
| Novartis Pharmaceuticals Corporation · A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study To Assess the Efficacy and Safety of Qaw039 When Added To Standard of Care Asthma Therapy in Patients With Uncontrolled Asthma · 2020 | Their institution | $1,545 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized 52 Weeks Treatment Double Blind Triple Dummy Study To Assess the Efficacy and Safety of Qmf149 Compared With Mometasone Furoate and Salmeterol Fluticasone · 2020 | Their institution | $93 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 23.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1194733428
- Licence
- CA G25149California G25149: Current · expires 2027-04-30
- Trained
- University of California, San Francisco School of Medicine, 1972
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207K00000X (207K00000X)
- Mailing address
- 4050 Moorpark Ave, San Jose, CA, 95117
- NPI first listed
- 2006-08-03
- NPI last updated
- 2013-12-10
This is when the NPI record was last certified, not a medical board exam.